| |
[摘要]：Gout is the most common form of inflammatory arthritis in men over 40 years of age. Available drugs target various steps to lower serum urate levels and include the xanthine oxidase inhibitors allopurinol and febuxostat, as well as the uricosuric agents probenecid, sulfinpyrazone and benzbromarone. Current treatment options are limited, associated v/ith adverse events and often have an inadequate response. These factors have driven the need for the development of new and alternative agents to lower uric acid levels. In this context, lesinurad sodium (RDEA-594), an active metabolite of RDEA-806, was noted to have significant uricosuric effects by inhibiting solute carrier family 22 member 72 (urate anion exchanger 7, URATI). URATI is a primary transporter of uric acid. In clinical trials, lesinurad sodium has been well tolerated, with dose-dependent reductions in serum uric acid. Moreover, co-administration of xanthine oxidase inhibitors and lesinurad sodium can safely accelerate urate reduction in gout patients. |
|
